ACM
JANX icon

ADAR1 Capital Management’s Janux Therapeutics JANX Stock Holding History

ADAR1 Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-264,900
Closed -$6.12M – 241
2025
Q2 		$6.12M Hold
264,900
– – 0.94% 28
2025
Q1 		$7.15M Buy
+264,900
New +$9.99M 1.33% 19

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ADAR1 Capital Management's JANX Position: Q1 2026 in Review

ADAR1 Capital Management increased its Janux Therapeutics (JANX) stake by 22% in Q1 2026, buying an estimated $728K and bringing the position to 298,546 shares worth $4.15M. The position accounts for 0.24% of the portfolio, ranked #87.

ADAR1 Capital Management first reported a position in JANX in Q1 2024 and has held it in 9 quarters since. The position peaked at $8.58M in Q3 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • ADAR1 Capital Management held 298,546 shares of Janux Therapeutics worth $4.15M as of Q1 2026.
  • ADAR1 Capital Management bought 53,094 Janux Therapeutics shares in Q1 2026, an estimated $728K.
  • Janux Therapeutics made up 0.24% of ADAR1 Capital Management's portfolio in Q1 2026, its #87 holding.
  • ADAR1 Capital Management first reported a position in Janux Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • ADAR1 Capital Management's Janux Therapeutics position peaked at $8.58M in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.